> Home
 
  > About
 
  > Portfolio
 
  > News
 
  > Documents for download
 
  > Investors
 
  > Press Room
 
  > Policies and Ethics
 
  > Contact
 
  > Links


Karolinska Development
AB (publ)
org. nr. 556707-5048
Registered office: Solna
© Karolinska Development 2008

 

 

NeuroTherapeutics AB

NeuroTherapeutics aims to treat Parkinson’s Disease by delivering products/services to "directed" stem cells to expand and differentiate towards the desired dopamine producing neuron. Technologies that promote neuronal survival are also under development.

Contact
Staffan Söderström, CEO
  +46 8 508 845 80
 
  www.neurotherapeutics.se

 

 

 
 

Actar AB
Akinion Pharmaceuticals AB
Aprea AB
Athera Biotechnologies AB
Avaris AB
Axelar AB
BioArctic Neuroscience AB
BioChromix Pharma AB
Biocis Pharma Ltd.
Bioneris AB
BioResonator AB
Biosergen A/S
Clanotech AB
Cytoguide
DermaGen AB
Dilafor AB
Eribis Pharmaceuticals AB
HBV Theranostica AB
IMED AB
Independent Pharmaceutica AB
InDex Pharmaceuticals AB
Inhalation Sciences Sweden AB
Lipopeptide AB
NeoDynamics AB
NephroGenex Inc.
NeuroTherapeutics AB
NovaSAID AB
Omnio Healer AB
Oncopeptides AB
Pergamum AB
PharmaSurgics AB
Promimic AB
ProNoxis AB
Umecrine AB
Umecrine Cognition AB
Umecrine Mood AB
XSpray Microparticles AB